Complement‑targeted therapeutics continue to expand, with C3, C5, and alternative‑pathway inhibitors advancing through clinical pipelines. Creative Biolabs’ complement assay kit suite spans the ...

Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...

Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES ...